GlassScriptPhysician profile
Adnan A Ayoub
NPI 1639646086
$5,915.19
in general payments reported to CMS, 2019-2025
20 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $694 · 2022: $1,171 · 2023: $1,556 · 2024: $1,313 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,049.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,556.75 | 2021-2025 | Biktarvy |
| Viiv Healthcare Company | $1,488.88 | 2021-2025 | Dovato, Apretude, Rukobia |
| Theratechnologies INC. | $575.24 | 2022-2025 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $559.95 | 2021-2023 | Symtuza |
| Lilly USA, LLC | $334.71 | 2022-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $279.04 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Emd Serono, INC. | $273.00 | 2021-2025 | Serostim |
| Janssen Products, LP | $188.00 | 2021-2022 | |
| Exact Sciences Corporation | $123.63 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.56 | 2022-2024 | Xifaxan |
| Novo Nordisk INC | $79.10 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Vbi Vaccine (Delaware) INC. | $74.20 | 2022-2023 | Prehevbrio |
| Insulet Corporation | $57.64 | 2025 | Omnipod |
| Medtronic, INC. | $56.66 | 2025 | Closurefast |
| Idorsia Pharmaceuticals US INC | $47.64 | 2023 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.35 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.16 | 2025 | Caplyta |
| Endo Pharmaceuticals INC. | $20.51 | 2023 | Nascobal |
| Dynavax Technologies Corporation | $15.79 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.38 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Ayoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.